Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PN20 in Healthy Adult Volunteers
NCT06523088Phase 1Completed
- Sponsor
- Chongqing Peg-Bio Biopharm Co., Ltd.
- Start
- Jun 2022
- Primary completion
- Jan 2023
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in chemotherapy-induced thrombocytopenia (CIT) and immune thrombocytopenic purpura (ITP) comparing PN20 Group with Placebo Group (2 arms). Primary endpoint: Treatment-related Adverse Events up to 15 days. Started Jun 2022; status: completed.
02
Drugs
PJ004
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)immune thrombocytopenic purpura (ITP)
Beyond the preview
Go deeper on NCT06523088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06523088.